Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study

  • Karasawa K
  • Sunamura M
  • Okamoto A
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p=0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer.

Author-supplied keywords

  • Adult
  • Aged
  • Cell Hypoxia
  • Female
  • Humans
  • Imidazoles/adverse effects/*therapeutic use
  • Intraoperative Period
  • Male
  • Middle Aged
  • Pancreatic Neoplasms/mortality/*radiotherapy/surge
  • Radiation-Sensitizing Agents/adverse effects/*ther
  • Survival Rate

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • K Karasawa

  • M Sunamura

  • A Okamoto

  • K Nemoto

  • S Matsuno

  • Y Nishimura

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free